Novavax | NVAX - Beneficio Bruto En Ventas

Precio De Mercado
8.45
Cambio Diario
-0.50 -5.59%
Mensual
-16.42%
Anual
20.71%
Q1 Expectativa
8.20




Beneficio Bruto En Ventas Cambio Fecha
Adma Biologics USD 88.82M 13.19M 2025-12
Agenus USD 34.2M 4.61M 2025-12
AstraZeneca USD 12.39B 5M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Cassava Sciences USD -3.96M 1.16M 2025-09
Geron USD 46.71M 525K 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
MannKind USD 78.31M 76.21M 2025-12
Merck USD 13.42B 431M 2025-09
Minerva Neurosciences -4.27M 26.79M 2024-12
Moderna USD 226M 583M 2025-12
Novartis USD 10.82B 694M 2025-09
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
TG Therapeutics USD 154.43M 20.81M 2025-12